Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Current status and future directions

Seminars in Oncology

Volumn 27, Issue 4, 2000, Pages 25-33

  Khuri, F R ^a   Shin, D M ^a   Glisson, B S ^a   Lippman, S M ^a   Hong, W K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; MESNA; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; ONCOLYTIC VIRUS; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SIGNAL TRANSDUCTION INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CLINICAL TRIAL; DRUG INDUCED DISEASE; HEAD CANCER; HUMAN; MAXIMUM PERMISSIBLE DOSE; METASTASIS; NECK CANCER; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; HEAD AND NECK NEOPLASMS; HUMANS; IFOSFAMIDE; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; TAXOIDS; VINBLASTINE;

EID: 0033892116     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Head and neck cancer
2. Head and neck cancer
3. Impact of improved local control on survival
4. Treatment failure in head and neck cancer
5. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck
6. Randomized comparison of cisplatin, methotrexate, bleomycin, and vincristine (VABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group
7. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study
8. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel
9. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (PA390)
10. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies
11. A phase III trial of high-dose paclitaxel + cisplatin + G-CSF versus low-dose paclitaxel + cisplatin in patients with advanced squamous cell carcinoma of the head and neck (HNSCC): An Eastern Cooperative Oncology Group trial
12. Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck
13. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma
14. Chemotherapy for relapsed head and neck cancer: Paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study
15. Combination of cisplatinum (CDDP), 5-fluorouracil (5-FU) and paclitaxel in the treatment of patients with advanced/recurrent squamous cell carcinoma of the head and neck (SCCHN). Updated results
16. Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: Preliminary results of phase II trial
17. Phase II study of paclitaxel, ifosfamide, and carboplatin (TIC) in patients (PTS) with recurrent squamous cell carcinoma of the head and neck (SCCHN)
18. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells
19. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group
20. Docetaxel: An active drug for squamous cell carcinoma of the head and neck
21. A late phase II study of docetaxel (Taxotere) in patients with head and neck cancer (HNC)
22. Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group
23. A phase II study of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (5-FU) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NC)
24. A phase II study of docetaxel and cisplatin in patients with locally advanced, recurrent, and/or metastatic squamous cell carcinoma of the head and neck (SCCHN), not curable by standard therapy
25. Clinical results of docetaxel (D) and 5-fluorouracil (5FU) in metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN)
26. Phase I-II study with docetaxel (D), cisplatin (C) and 5-fluorouracil (5FU) in patients (pts) with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN)
27. Docetaxel (DTX) and cisplatin (CDDP) in locally advanced or metastatic head and neck cancer (HN). A phase II study
28. Ifosfamide in advanced head and neck cancer: A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group
29. Activity of ifosfamide (NSC-109724) in recurrent head and neck cancer patients
30. Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer
31. Ifosfamide in advanced epidermoid head and neck cancer
32. A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck
33. Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study
34. Gemcitabine: Preclinical pharmacology and mechanisms of action
35. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group
36. Phase II trial of cisplatin (C) and gemcitabine (G) in advanced squamous cell carcinoma of the head and neck (AHNC)
37. Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients
38. A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
39. An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
40. A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck
41. Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: A multicenter phase II trial
42. A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC)
43. Ras protein farnesyl transferase: A strategic target for anticancer therapeutic development